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Abstract
Background: Dual rapid tests for HIV and syphilis infections allow for detection of HIV infection and syphilis at the
point-of-care. Those tests have been evaluated in laboratory settings and show excellent performance but have not
been evaluated in the field. We evaluated the field performance of the SD BIOLINE HIV/Syphilis Duo test in
Port-au-Prince, Haiti using whole blood fingerprick specimens.
Methods: GHESKIO (Haitian Study Group for Kaposi’s Sarcoma and Opportunistic Infections) clinic attendees
18 years of age or older were invited to participate. Venipuncture blood specimens were used for reference testing
with standard commercially available tests for HIV and syphilis in Haiti. The sensitivity and specificity of the Duo test
compared to the reference standard were calculated. The exact binomial method was used to determine 95 %
confidence intervals (CI).
Results: Of 298 study participants, 237 (79.5 %) were female, of which 49 (20.7 %) were pregnant. For the HIV test
component, the sensitivity and specificity were 99.2 % (95 % CI: 95.8 %, 100 %) and 97.0 % (95 % CI: 93.2 %, 99.0 %),
respectively; and for the syphilis component were 96.5 % (95 % CI: 91.2 %, 99.0 %) and 90.8 % (95 % CI: 85.7 %, 94.6 %),
respectively. In pregnant women, the sensitivity and specificity of the HIV test component were 93.3 % (95 % CI: 68.0 %,
99.8 %) and 94.1 % (95 % CI: 80.3 %, 99.3 %), respectively; and for the syphilis component were 100 % (95 % CI:81.5 %,
100 %) and 96.8 % (95 % CI:83.3 %, 99.9 %), respectively.
Conclusion: The Standard Diagnostics BIOLINE HIV/Syphilis Duo dual test performed well in a field setting in Haiti and
should be considered for wider use.
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Background
HIV and syphilis infections cause substantial burden of
disease [1–3]. Those with syphilis may be asymptomatic
but if left untreated, syphilis can lead to continued trans-
mission, neurological complications, and in pregnant
women can result in severe adverse outcomes of preg-
nancy. Transmission and complications that occur as a
result of infection can be prevented through early testing
and subsequent treatment for those who test positive.
Up to 80 % of syphilis infections in pregnancy cause
adverse outcomes including stillbirths or fetal deaths,
neonatal deaths, preterm or low birth weight infants,
and infants born with congenital disease [4]. In addition,
syphilis infection in HIV infected pregnant women leads
to a 2.7 fold increase in the risk of mother-to-child
transmission of HIV infection [5]. In order to address
the risk of adverse outcomes of pregnancy and the
mother-to-child transmission of both HIV and syphilis,
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the World Health Organization has called for the dual
elimination of HIV and syphilis [6].
Integrating the screening of syphilis into HIV prevention
programs would add little to the cost of screening but
would have a major effect on case finding of both syphilis
and HIV and the prevention of transmission [7, 8]. Syph-
ilis and HIV dual testing provides the opportunity to test
for both infections using one drop of blood collected with
a fingerprick with one device in minutes, allowing for
same-day testing and treatment. Dual testing is warranted
because both syphilis and HIV infections have evidence-
based, scalable interventions using the antenatal care plat-
form for pregnant women [9–11]. Mother-to-child trans-
mission of HIV and syphilis can be prevented through
early access to antenatal care, testing and treatment. With
the advent of dual testing, HIV and syphilis have afford-
able and accurate point-of-care integrated tests making it
feasible for use in any setting – not just those with labora-
tory capacity. A dual point-of-care test has the potential to
reduce missed opportunities to return results and can im-
prove efficiency along the treatment cascade [11, 12]. The
recent development of a new dual rapid HIV and syphilis
test is ideal for Haiti, a country with limited resources. In
Haiti 90 % of pregnant women report at least one ante-
natal visit [13]. Therefore, by including rapid syphilis
screening in the first antenatal visit, 90 % of pregnant
Haitian women could have access to testing and treatment.
The SD BIOLINE HIV/Syphilis Duo test is a qualita-
tive solid phase immunochromatographic assay. It is
easy to perform and interpret and does not require
special storage or transport conditions with results avail-
able in 20 min. The test has been shown to be highly
sensitive and specific in laboratory settings using plasma
and serum [14–18]. However, rapid tests are intended
for use at the point-of-care using a fingerprick whole
blood specimen. We evaluated the performance of the
SD BIOLINE HIV/Syphilis Duo test in Port-au-Prince,
Haiti using whole blood fingerprick specimens.
Methods
Participants included men and women, at least 18 years of
age from GHESKIO (Haitian Study Group for Kaposi’s
sarcoma and Opportunistic Infections) clinics in Port-au-
Prince, Haiti enrolled from March through July 2014.
Working in partnership with the Haitian Government,
GHESKIO is a nonprofit organization that provides inte-
grated primary care services, including HIV counseling,
AIDS care, antenatal care, and management of tuber-
culosis and sexually transmitted infections. GHESKIO
receives about 100,000 patient visits annually and all of
the health care provided by GHESKIO is free of charge,
including services and medications. Known pregnant
women were actively recruited for participation at the
GHESKIO antenatal clinic. Additionally, known HIV and
syphilis-infected participants were actively recruited to
supplement the study population.
After participants gave their informed consent, a
trained health worker collected a single drop of blood
from the participant using a fingerprick. The SD BIO-
LINE HIV/Syphilis Duo test (Standard Diagnostics,
Giheung-gu, Korea) was conducted using the whole
blood fingerprick specimen according to the manufac-
turer’s instructions. In short, the participant’s finger was
pricked with a lancet, a capillary pipette was used to col-
lect one drop of blood, the drop of blood was added into
the test ‘sample well’ followed by 3 drops of buffer solu-
tion. After 20 min the health worker read the test results.
The presence of a color band for the control, marked as
‘C’, indicated a valid test. At two other regions marked
with ‘SYP’ and ‘HIV’ color bands appeared to indicate
positive results. Additionally, the visual intensity of the
color band indicating a positive result was recorded by the
health worker using the color intensity standard (Fig. 1).
The visual color intensity was recorded on a 100-point
scale by two separate health workers. We analyzed the
average color intensity result between the two.
From the study participants, venipuncture blood speci-
mens were collected by phlebotomists and transported
to the reference laboratory for serum separation and
reference testing. HIV reference testing varied depending
on which clinic at GHESKIO participants presented. The
reference tests included the Murex HIV-1.2.0 (DiaSorin
S.p.A., Saluggia, Italy) or Alere Determine HIV (Alere Inc.,
Waltham, MA) rapid tests. Positive results from either test
were confirmed with the KHB rapid test (Shanghai Kehua
Bio-Engineering Co., LTD, China). For the rapid Trepo-
nema pallidum antibody reference test, we used the
Treponema Pallidum Hemagglutination Assay (TPHA)
Fig. 1 Standard for band color intensity for SD BIOLINE HIV/Syphilis Duo dual rapid test. The color bands on this reference standard were
compared to positive results on the Duo test and the percent intensity was recorded by two trained phlebotomists
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(Human Gesellschaft fur Biochemica und Diagnostica
mbH, Wiesbaden, Germany). For TPHA indeterminate
results, specimens were retested using a Treponema palli-
dum enzyme-linked immunosorbent assay test (ELISA)
(Architect Syphilis TP; Abbott, Wiesbaden, Germany).
Rapid plasma reagin (RPR) (Syphilis RPR test, Human
Gesellschaft fur Biochemica und Diagnostica mbH,
Wiesbaden, Germany) results were also available for
all participants to assist with clinical diagnosis. RPR
titer levels were determined using serial dilutions.
The sensitivity and specificity of the SD BIOLINE were
calculated for the whole study population and for the
subset of pregnant women. We also analyzed the results
by RPR titer, ≤1:4 and >1:4 because a titer of more than
1:4 is likely to be a recent infection. The exact binomial
method was used to determine 95 % confidence intervals
(CI) [14]. The Kappa statistic was used to determine
concordance between the rapid Duo test and reference
test results. Visual color intensity for positive results was
summarized using descriptive statistics. All analyses were
conducted using SAS v9.3 (Cary, North Carolina, USA).
The Institutional Review Board at GHESKIO Centers gave
ethical approval for this study.
Results
Of 298 study participants, 61 (20.5 %) were male. Of
237 females, 49 (20.7 %) were pregnant. The median
age of participants was 34 years (interquartile range:
26, 42). All participants had a Duo rapid test and refer-
ence tests for antibodies to HIV and syphilis. Of the
298 participants, 21 had inconclusive TPHA results. Of
those 21 inconclusive results, all (100 %) were Trepo-
nema pallidum ELISA positive and 15 (71.4 %) were
RPR positive.
The test performance results can be seen in Tables 1
and 2. For the HIV component, the sensitivity and speci-
ficity were 99.2 % (95 % CI: 95.8 %, 100 %) and 97.0 %
(95 % CI: 93.2 %, 99.0 %), respectively. For the Trepo-
nema pallidum component, the sensitivity and specifi-
city were 96.5 % (95 % CI: 91.2 %, 99.0 %) and 90.8 %
(95 % CI: 85.7 %, 94.6 %), respectively. Two of the 17
false positive results (Duo Treponema pallidum positive,
TPHA negative) were reactive on the RPR test with
titers of 1:4 and 1:64. Among those with higher RPR
titers (treponemal antibody positive and RPR > 1:4), the
sensitivity for the Treponema pallidum component of
the test was 97.4 % (95 % CI: 86.5 %, 99.9 %). Addition-
ally, among HIV positive specimens the performance for
the Treponema pallidum component of the Duo test
had a sensitivity of 94.4 % (95 % CI: 72.7 %, 99.9 %) and
a specificity of 92.8 % (95 % CI: 86.3 %, 96.8 %) and
among HIV negative specimens the sensitivity was
96.8 % (95 % CI: 91.1 %, 99.3 %) and the specificity was
87.8 % (95 % CI: 78.2 %, 94.3 %).
In pregnant women, the sensitivity and specificity of
the HIV component were 93.3 % (95 % CI: 68.0 %,
99.8 %) and 94.1 % (95 % CI: 80.3 %, 99.3 %), respectively.
For the Treponema pallidum component the sensitivity
and specificity were 100 % (95 % CI: 81.5 %, 100 %) and
96.8 % (83.3 %, 99.9 %), respectively.
The color line indicating a positive result on the Duo
test tended to be more intense (darker) for the HIV anti-
body component (median intensity =100 %) of the positive
tests versus the Treponema pallidum antibody component
(median intensity = 20 %) (Table 3). Additionally, the
color band intensity was lower among false positive
test results for both HIV and syphilis results than
among true positive results.
Discussion
We evaluated a dual rapid point-of-care test for the
detection of HIV and syphilis infection in fingerprick
whole blood specimens. The HIV antibody component
of the dual test showed excellent performance with a
sensitivity of 99.2 % and specificity of 97 %. That high
performance using whole blood is similar to what was
observed in laboratory evaluations using serum or
plasma [14–16, 18]. That high performance suggests the
dual test could be used at the point-of-care with whole
blood fingerprick specimens as a screening test. The
few false positive HIV results that were found rein-
forces the need for HIV confirmatory testing for those
who screen positive.
The Treponema pallidum antibody component was
highly sensitive however the specificity was somewhat
lower. False positives could have resulted because the
reference test may use different antibody targets than the
Duo test, which utilizes Tp0435 (TpN17) recombinant
Table 1 Field performance of the SD BIOLINE HIV/Syphilis Duo dual rapid test in Haiti for detection of HIV antibodies using a dual
HIV/syphilis test, 2014
HIV reference test* Total Sensitivity (95 % CI) Specificity (95 % CI) Kappa Coefficient (95 % CI)
Pos Neg
SD BIOLINE HIV/Syphilis Duo test Pos 128 5 133 99.2 % (95.8 %, 100 %) 97.0 % (93.2 %, 99.0 %) .96
Neg 1 164 165 (.93, .99)
Total 129 169 298
*Reference tests were Murex HIV-1.2.0 (DiaSorin S.p.A., Saluggia, Italy) or Alere Determine HIV (Alere) rapid testing. Positive results were confirmed with a colloidal
gold test from KHB (Shanghai Kehua Bio-Engineering Co., LTD, China)
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Treponema pallidum antigen as the target. Additionally,
other reactive antibodies could be responsible for the false
positive results observed with the Duo test. We also
calculated the performance of the Treponema pallidum
component of the Duo test stratified by HIV status and
found that differences were small with overlapping
confidence intervals and therefore are unlikely to be
clinically significant.
Among our sample of nearly 300 participants, the Duo
gave 17 Treponema pallidum false positive results. Of
which, two were RPR reactive indicating that these may
be falsely negative on the reference test. If we reclassified
those as true positives then there would be a slight
increase in specificity. That finding highlights the limita-
tions of using an imperfect reference test to determine
validity of a new test.
A limitation of all syphilis tests is that they can pro-
duce false negative results when the infection has been
acquired very recently [19]. Additional limitations occur
with treponemal only tests because treponemal anti-
bodies can persist for life, even following curative treat-
ment. Therefore rapid tests for syphilis which detect
treponemal antibodies will give a positive result if there
is a history of syphilis infection. In some settings con-
firmatory tests may be necessary while in others – such
as antenatal clinics – the benefits of providing same day
syphilis treatment might outweigh the risks of unneces-
sary treatment [20]. A limitation of our study was that
we had a modest sample size and used a population of
participants from a single city in Haiti. However, because
of consistency of the test performance across multiple
study populations in various countries, we would not
expect those limitations to have a substantial impact
[14]. An additional limitation is that for both HIV and
syphilis, more than one reference test was used that may
not provide the same level of accuracy, although all tests
are acceptable validated tests.
Among pregnant women, we found that the Trepo-
nema pallidum component of the dual test actually
had similar or potentially higher sensitivity and speci-
ficity compared with the total study population. The
risks of untreated syphilis infection in pregnancy are
very high and an accurate screening test to detect
syphilis is paramount to reduce adverse pregnancy
outcomes [4, 6]. The HIV component of the test in
pregnant women showed similar and possible some-
what lower performance than among non-pregnant
participants, however the sample size was small and
the lower performance could be due to random error.
Identification of HIV in pregnancy and subsequent
intervention is paramount to reduce the burden of
mother-to-child HIV transmission.
The color band intensity was subjective. Using an
electronic rapid test reader would provide an objective
reading of the color band intensity to further explore
this relationship [21]. The manufacturer instructions
indicate that any color band should be interpreted as a
positive result. In our study, false positive results pro-
vided a much lower color intensity reading, however due
to the substantial overlap in color intensity between false
and true positive results, we could not determine an
accurate cutoff value.
Table 2 Field performance of the SD BIOLINE HIV/Syphilis Duo dual rapid test in Haiti for detection of Treponema pallidum
antibodies using a dual HIV/syphilis test, 2014
Treponema pallidum
reference test*
Total Sensitivity (95 % CI) Specificity (95 % CI) Kappa Coefficient (95 % CI)
Pos Neg
SD BIOLINE HIV/Syphilis Duo test Pos 109 17 126 96.5 % (91.2 %, 99.0 %) 90.8 % (85.7 %, 94.6 %) .85
Neg 4 168 172 (.79, .91)
Total 113 185 298
*Reference test was conducted using Treponema Pallidum Hemaglutination Assay (TPHA) (Human Gesellschaft fur Biochemica und Diagnostica mbH, Wiesbaden,
Germany). TPHA indeterminate results were retested using a Treponema pallidum enzyme-linked immunosorbent assay test (ELISA)(Architect Syphilis TP; Abbott,
Wiesbaden, Germany) and were reclassified based on the ELISA result
Table 3 Visual intensity of the color of the bands indicating positive results for the SD BIOLINE HIV/Syphilis Duo dual rapid test
N Mean (%) Standard deviation (%) Median (%) Quartile range (%) Minimum (%) Maximum (%)
HIV band color intensity 133 88.3 28.0 100 0 0.3 100
HIV true positives 128 91.7 22.4 100 0 0.3 100
HIV false positives 5 1.3 2.1 0.3 0.4 0.3 5.0
T. pallidum band color intensity* 126 30.3 31.9 20 37 0.3 100
T. pallidum true positives 109 34.3 32.4 23 40 0.3 100
T. pallidum fase positives 17 4.8 7.1 2 4 0.3 26
*Note: Intensity was not recorded for three of the tests that were syphilis positive on the Duo test
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Conclusions
The Duo dual rapid syphilis and HIV test is ideal for use
in resource-limited settings where laboratory services
are often unavailable and follow-up may be difficult. By
testing for HIV and syphilis with a single device and one
drop of blood from a fingerprick and affordable through
bulk procurement at US$1.10, the Duo test has the
potential to reduce testing barriers and increase uptake
of testing for both HIV and syphilis. The SD BIOLINE
Duo test was accurate in this field setting in Haiti and
should be considered for expanded use to increase the
uptake of dual screening for HIV infection and syphilis.
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